I have read and accept the Wiley Online Library Terms and Conditions of Use, Surveillance, Epidemiology, and End Results (SEER) Program, SEER*Stat Database: Incidence‐SEER 9 Regs Research Data with Delay‐Adjustment, Malignant Only, based on the November 2018 submission, Breast Schema for 1988‐2015 Based on AJCC 6th Edition, SEER*Stat Database: Incidence‐SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2018 Submission (2000‐2016)
‐Linked To County Attributes‐Total U.S., 1969‐2017 Counties, SEER*Stat Database: North American Association of Central Cancer Registries (NAACCR) Incidence Data‐Cancer in North America (CiNA) Analytic File, 1995‐2015, for NHIAv2 Origin, Custom File With County, American Cancer Society (ACS) Facts and Figures Projection Project (which includes data from the Centers for Disease and Prevention's [CDC's] National Program of Cancer Registries [NPCR], the Canadian Council of Cancer Registry's [CCCR's] Provincial and Territorial Registries, and the National Cancer Institute's [NCI's] SEER Registries), SEER*Stat Database: North American Association of Central Cancer Registries (NAACCR) Incidence Data‐Cancer in North America (CiNA) Analytic File, 1995‐2016, for Expanded Races, Custom File With County, American Cancer Society (ACS) Facts and Figures Projection Project (which includes data from the Centers for Disease and Prevention's [CDC's] National Program of Cancer Registries [NPCR], the Canadian Council of Cancer Registry's [CCCR's] Provincial and Territorial Registries, and the National Cancer Institute's [NCI's] SEER Registries), Surveillance, Epidemiology, and End Results (SEER) Program (seer.cancer.gov), SEER*Stat Database: Mortality ‐ All COD, Total U.S. (1969‐2017) ‐ Linked To County Attributes ‐ Total U.S., 1969‐2017 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released May 2019.
In black women, the incidence rate for HR‐positive breast cancer increased 2.8% per year during 2004 through 2011, but has since stabilized. Journal of Plastic, Reconstructive & Aesthetic Surgery. The interaction between MALAT1 target, miR-143-3p, and RALGAPA2 is affected by functional SNP rs3827693 in breast cancer.
Effective anti-aromatase therapy to battle against estrogen-mediated breast cancer: Comparative SAR/QSAR assessment on steroidal aromatase inhibitors. ceRNA network development and tumour-infiltrating immune cell analysis of metastatic breast cancer to bone. In contrast, incidence rates for triple‐negative breast cancers are about twice as high in blacks (38 per 100,000) compared with whites (19 per 100,000). The black‐white breast cancer disparity peaked in 2011 with death rates 44% higher in blacks than in whites (30.2 per 100,000 compared with 20.9 per 100,000, respectively). Growth inhibitory and anti-metastatic activity of epithelial cell adhesion molecule targeted three-way junctional Delta-5-Desaturase siRNA nanoparticle for breast cancer therapy.
We gratefully acknowledge all cancer registries and their staff for their hard work and diligence in collecting cancer information, without which this research could not have been done. Current Opinion in Endocrine and Metabolic Research. There was no statistically significant difference in the breast cancer death rate between black and white women in 8 states, although this may reflect a lack of statistical power (ie, a small number of breast cancer deaths in black women) except for Massachusetts (MRR, 1.11; 95% CI, 0.97‐1.26). Nedd8-activating enzyme inhibitor MLN4924 (Pevonedistat), inhibits miR-1303 to suppress human breast cancer cell proliferation via targeting p27Kip1.
The Journal of Clinical Endocrinology & Metabolism. Approximately 13% of women (1 in 8) will be diagnosed with invasive breast cancer in their lifetime (Table 2). Eighty‐two percent of breast cancers are diagnosed among women aged ≥50 years, and 90% of breast cancer deaths occur in this age group (Table 1). Nanomedicine: Nanotechnology, Biology and Medicine. While breast cancer death rates have remained steady since 2007 for women under 50 years old, the death rate for older women decreased by 1.3 percent each year from 2013 to 2017. Diosgenin Exerts Antitumor Activity via Downregulation of Skp2 in Breast Cancer Cells. In contrast, HR‐negative tumors decreased in all racial/ethnic groups by 1.5%‐2.6% per year. Community outreach and integration of breast radiologists.
The age‐specific probability of developing breast cancer (2014‐2016) was calculated using the NCI's DevCan software (version 6.7.7).16, In 2019, approximately 268,600 new cases of invasive breast cancer and 48,100 cases of DCIS will be diagnosed among US women, and 41,760 women will die from this disease. For example, APIs have the second highest rate of HR‐positive/HER2‐negative breast cancer among younger women (46 per 100,000, only slightly lower than in young white women, 51 per 100,000), but they have the lowest rate among older women (177 vs 275 per 100,000 in whites). All incidence and death rates were age‐standardized to the 2000 US standard population and expressed per 100,000 women, as calculated by the NCI's SEER*Stat software (version 8.3.5).14 We examined trends in incidence and mortality rates using the Joinpoint Regression Program to calculate AAPC.15 All incidence trends were adjusted for delays in reporting based on SEER delay factors to account for the additional time required for the complete registration of cases. For example, a recent study reported that the prevalence of the triple‐negative subtype in black women in the United States varied substantially by country of birth; compared with US‐born blacks, the prevalence was 47% lower in women born in countries in Eastern Africa but only 8% lower in Western Africa‐born blacks.21 In another study of women in California, those of Korean, Filipina, Chinese, and Southeast Asian descent had a higher risk of HER2‐positive breast cancers compared with white women, whereas those of Japanese and Asian Indian descent had a lower risk.22 Differences in breast cancer subtype within and between racial/ethnic groups likely reflect variations in the prevalence of breast cancer risk factors23 and mammography use,24 but may also be related to genetic variations.21, 25-27, Much of the historic increase in breast cancer incidence rates reflects changes in reproductive patterns, such as delayed childbearing and fewer births, associated with increased breast cancer risk.28 During the 1980s and 1990s, incidence rates of DCIS and invasive breast cancer rose rapidly, particularly among women aged ≥50 years (Fig. 1). Reasons for the divergent trends are not known but likely reflect changes in subtype‐specific breast cancer risk factors. Exploring the Effect of Post-mastectomy complications on 5-year survival.
Risk factors of distant metastasis after surgery among different breast cancer subtypes: a hospital-based study in Indonesia.
Learn more. Long non-coding RNA HUMT hypomethylation promotes lymphangiogenesis and metastasis via activating FOXK1 transcription in triple-negative breast cancer.
Underlying mortality data provided by NCHS (cdc.gov/nchs), SEER*Stat Database: Mortality‐All COD, Aggregated With State, Total U.S. (1990‐2017) , Cancer treatment and survivorship statistics, 2019, American College of Surgeons Commission on Cancer, National Cancer Database, 2016 Data Submission, Incident cases captured in the National Cancer Database compared with those in U.S. population based central cancer registries in 2012‐2014, Centers for Disease Control and Prevention, Behavioral Risk Factor Surveillance System Survey Data 2016, Incidence of breast cancer in the United States: current and future trends, Surveillance Research Program, National Cancer Institute, Joinpoint Regression Program, Version 4.7.0.0, DevCan: Probability of Developing or Dying of Cancer Software, Version 6.7.7, SEER Cancer Statistics Review, 1975‐2016. Echinacoside inhibits breast cancer cells by suppressing the Wnt/β-catenin signaling pathway. Similarly, for joint categories of ER, PR, and HER2, we first imputed HR status among cases with known HER2 status.
6). Antibiotic use and the risk of breast cancer: A systematic review and dose-response meta-analysis. Nevertheless, the death rate remains 40% higher in blacks (28.4 vs 20.3 deaths per 100,000) despite a lower incidence rate (126.7 vs 130.8); this disparity is magnified among black women aged <50 years, who have a death rate double that of whites. Then, we allocated those with unknown HER2 status to the 4 subtypes according to their updated distributions obtained in the previous step. Chemopreventive and Chemotherapeutic Effect of Propolis and Its Constituents: A Mini-review. In 2019, an estimated 268,600 new cases of invasive breast cancer will be diagnosed among women (Table 1) and approximately 2,670 cases will be diagnosed in men. Death rates have been steady in women under 50 since 2007, but have continued to drop in women over 50.
Note: Incidence and mortality rates are per 100,000 and are age‐adjusted to the 2000 US standard population.
Rasal2, highlighting the importance of phosphorylation on function in tumour development. Arctigenin inhibits proliferation of ER-positive breast cancer cells through cell cycle arrest mediated by GSK3-dependent cyclin D1 degradation. During 2013 through 2017, breast cancer death rates decreased in all states except Nebraska. AIAN indicates American Indian/Alaska Native; API, Asian/Pacific Islander; NHB, non‐Hispanic black; NHW, non‐Hispanic white.
Female breast cancer incidence and mortality rates by race/ethnicity are shown in Figure 1. The Evolving Landscape of HER2-Directed Breast Cancer Therapy. By using the approach of Anderson et al,13 we imputed missing estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status assuming that status was missing at random, conditional on year of diagnosis, age, race/ethnicity, and ER/PR/HER2 status. Environment and COVID-19: Pollutants, impacts, dissemination, management and recommendations for facing future epidemic threats. These estimates were also partially adjusted for expected reporting delays using invasive delay factors. 11).